Low incidence of anti-interferon-alpha antibodies in patients treated with interferon-alpha-2a for AIDS-associated Kaposi's sarcoma.
Anti-interferon (IFN)-alpha antibodies were determined in the serum of 28 patients treated with high-dose human recombinant IFN-alpha-2a for AIDS-associated Kaposi's sarcoma. After a median treatment duration of 3 months, 3 patients developed anti-IFN-alpha antibodies, of whom 2 showed a long lasting tumour response despite the development of these antibodies. None of 3 patients with tumour progression after an initial treatment response had developed IFN-alpha neutralizing antibodies. In conclusion, a low incidence of anti-IFN-alpha antibodies during treatment with high dose IFN-alpha was found, but the appearance had no detrimental effect on the duration of tumour responses in a small number of patients.
de Wit
R
R
Division of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands.
Bakker
P J
PJ
Danner
S A
SA
Goudsmit
J
J
Veenhof
K H
KH
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000906:Antibodies / Q000097:blood*; D000917:Antibody Formation; D006801:Humans; D007370:Interferon Type I / Q000276:immunology*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D011994:Recombinant Proteins; D012514:Sarcoma, Kaposi / Q000209:etiology / Q000628:therapy*
D000906:Antibodies; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins